Abstract
A mutant HSV (mtHSV) deleted icp34.5, an apoptosis-inhibiting gene was constructed. It is supposed that the mtHSV can replicate in p53-deficient cells selectively and lead to oncolysis targetedly. Mice tumor model harboring sarcoma cell line s-180 was developed and the mtHSV was injected into the tumors. We found that the mean volume and weight of tumors of early therapeutic group(ETG) were reduced 49.29% and 38.31% of that of control tumors. In the mid-term group (MTG), the redutcion rate were 26.9% and 24.52% respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bischoff J R, Kim D H, Willams A,et al. An Adenovirus Mutant That Replicate Selectively in p53-Deficent Human Tumor Cells.Science, 1996,274:373–376.
Xiao Geng-fu. Study on Target Gene Therapy for Cancer With Apoptois-inducing/inhibiting Virus: [Doctor of Philosophy Thesis]. Wuhan Univ: Library of Wuhan Univ. 1999(Ch).
Author information
Authors and Affiliations
Additional information
Foundation item: Supported by Foundation of 863 New Hi-technique Research (39880031); Research Fund for the Doctoral Programm of Higher Education (RFDP98048615); Chen-guang Project of Wuhan City (20005004024).
Biography: Lan Ping (1971-), female, Ph.D candidate, research direction: molecular virology.
Rights and permissions
About this article
Cite this article
Ping, L., Yi-peng, Q. & Geng-fu, X. Gene therapy for cancer by mutant HSV deleted apoptosis-inhibited gene. Wuhan Univ. J. Nat. Sci. 5, 377–378 (2000). https://doi.org/10.1007/BF02830160
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02830160